{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:58:24Z","timestamp":1791230304066,"version":"4.1.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Tumor immunosurveillance plays a major role in melanoma, prompting the development of immunotherapy strategies. The gut microbiota composition, influencing peripheral and tumoral immune tonus, earned its credentials among predictors of survival in melanoma. The MIND-DC phase III trial (NCT02993315) randomized (2:1 ratio) 148 patients with stage IIIB\/C melanoma to adjuvant treatment with autologous natural dendritic cell (nDC) or placebo (PL). Overall, 144 patients collected serum and stool samples before and after 2 bimonthly injections to perform metabolomics (MB) and metagenomics (MG) as prespecified exploratory analysis. Clinical outcomes are reported separately. Here we show that different microbes were associated with prognosis, with the health-related\n                    <jats:italic>Faecalibacterium prausnitzii<\/jats:italic>\n                    standing out as the main beneficial taxon for no recurrence at 2 years (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.008 at baseline, nDC arm). Therapy coincided with major MB perturbations (acylcarnitines, carboxylic and fatty acids). Despite randomization, nDC arm exhibited MG and MB bias at baseline: relative under-representation of\n                    <jats:italic>F. prausnitzii<\/jats:italic>\n                    , and perturbations of primary biliary acids (BA).\n                    <jats:italic>F. prausnitzii<\/jats:italic>\n                    anticorrelated with BA, medium- and long-chain acylcarnitines. Combined, these MG and MB biomarkers markedly determined prognosis. Altogether, the host-microbial interaction may play a role in localized melanoma. We value systematic MG and MB profiling in randomized trials to avoid baseline differences attributed to host-microbe interactions.\n                  <\/jats:p>","DOI":"10.1038\/s41467-024-45357-1","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T06:03:02Z","timestamp":1708668182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1920-142X","authenticated-orcid":false,"given":"Carolina","family":"Alves Costa Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1947-1817","authenticated-orcid":false,"given":"Gianmarco","family":"Piccinno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9borah","family":"Suissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9867-6807","authenticated-orcid":false,"given":"M\u00e9lanie","family":"Bourgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0156-8365","authenticated-orcid":false,"given":"Gerty","family":"Schreibelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylv\u00e8re","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanne","family":"Birebent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5589-9688","authenticated-orcid":false,"given":"Marine","family":"Fidelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciss\u00e9","family":"Sow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Aprahamian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0846-6529","authenticated-orcid":false,"given":"Paolo","family":"Manghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1915-9391","authenticated-orcid":false,"given":"Michal","family":"Pun\u010doch\u00e1\u0159","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3732-1468","authenticated-orcid":false,"given":"Francesco","family":"Asnicar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Armanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safae","family":"Terrisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1955-9149","authenticated-orcid":false,"given":"Bertrand","family":"Routy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9997-9727","authenticated-orcid":false,"given":"Damien","family":"Drubay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M. M.","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Kroemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1583-5794","authenticated-orcid":false,"given":"Nicola","family":"Segata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1596-0998","authenticated-orcid":false,"given":"Laurence","family":"Zitvogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Derosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalijn F.","family":"Bol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8653-4040","authenticated-orcid":false,"given":"I. Jolanda M.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"45357_CR1","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S0140-6736(13)60802-8","volume":"383","author":"AM Eggermont","year":"2014","unstructured":"Eggermont, A. M., Spatz, A. & Robert, C. Cutaneous melanoma. Lancet 383, 816\u2013827 (2014).","journal-title":"Lancet"},{"key":"45357_CR2","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","volume":"28","author":"ILM Reijers","year":"2022","unstructured":"Reijers, I. L. M. et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat. Med. 28, 1178\u20131188 (2022).","journal-title":"Nat. Med."},{"key":"45357_CR3","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1056\/NEJMoa060992","volume":"355","author":"DL Morton","year":"2006","unstructured":"Morton, D. L. et al. Sentinel-node biopsy or nodal observation in melanoma. N. Engl. J. Med. 355, 1307\u20131317 (2006).","journal-title":"N. Engl. J. Med."},{"key":"45357_CR4","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","volume":"16","author":"AMM Eggermont","year":"2015","unstructured":"Eggermont, A. M. M. et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 16, 522\u2013530 (2015).","journal-title":"Lancet Oncol."},{"key":"45357_CR5","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AMM Eggermont","year":"2016","unstructured":"Eggermont, A. M. M. et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N. Engl. J. Med. 375, 1845\u20131855 (2016).","journal-title":"N. Engl. J. Med."},{"key":"45357_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372, 30\u201339 (2015).","journal-title":"N. Engl. J. Med."},{"key":"45357_CR7","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320\u2013330 (2015).","journal-title":"N. Engl. J. Med."},{"key":"45357_CR8","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521\u20132532 (2015).","journal-title":"N. Engl. J. Med."},{"key":"45357_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010).","journal-title":"N. Engl. J. Med."},{"key":"45357_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","volume":"83","author":"S Ugurel","year":"2017","unstructured":"Ugurel, S. et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur. J. Cancer 83, 247\u2013257 (2017).","journal-title":"Eur. J. Cancer"},{"key":"45357_CR11","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long, G. V. et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N. Engl. J. Med. 377, 1813\u20131823 (2017).","journal-title":"N. Engl. J. Med."},{"key":"45357_CR12","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber, J. et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV Melanoma. N. Engl. J. Med. 377, 1824\u20131835 (2017).","journal-title":"N. Engl. J. Med."},{"key":"45357_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ejca.2021.02.012","volume":"148","author":"JM Versluis","year":"2021","unstructured":"Versluis, J. M. et al. Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. Eur. J. Cancer 148, 51\u201357 (2021).","journal-title":"Eur. J. Cancer"},{"key":"45357_CR14","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"388","author":"SP Patel","year":"2023","unstructured":"Patel, S. P. et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N. Engl. J. Med. 388, 813\u2013823 (2023).","journal-title":"N. Engl. J. Med."},{"key":"45357_CR15","doi-asserted-by":"publisher","first-page":"e378","DOI":"10.1016\/S1470-2045(19)30332-8","volume":"20","author":"RN Amaria","year":"2019","unstructured":"Amaria, R. N. et al. Neoadjuvant systemic therapy in melanoma: recommendations of the International neoadjuvant melanoma consortium. Lancet Oncol. 20, e378\u2013e389 (2019).","journal-title":"Lancet Oncol."},{"key":"45357_CR16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","volume":"27","author":"AM Menzies","year":"2021","unstructured":"Menzies, A. M. et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat. Med. 27, 301\u2013309 (2021).","journal-title":"Nat. Med."},{"key":"45357_CR17","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/PPO.0b013e3181eaca83","volume":"16","author":"K Palucka","year":"2010","unstructured":"Palucka, K., Ueno, H., Roberts, L., Fay, J. & Banchereau, J. Dendritic cells: are they clinically relevant? Cancer J. 16, 318\u2013324 (2010).","journal-title":"Cancer J."},{"key":"45357_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrc3258","volume":"12","author":"K Palucka","year":"2012","unstructured":"Palucka, K. & Banchereau, J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 12, 265\u2013277 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"45357_CR19","doi-asserted-by":"publisher","first-page":"e18801","DOI":"10.1371\/journal.pone.0018801","volume":"6","author":"A Draube","year":"2011","unstructured":"Draube, A. et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One 6, e18801 (2011).","journal-title":"PLoS One"},{"key":"45357_CR20","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1158\/1078-0432.CCR-15-1399","volume":"22","author":"KF Bol","year":"2016","unstructured":"Bol, K. F., Schreibelt, G., Gerritsen, W. R., de Vries, I. J. M. & Figdor, C. G. Dendritic cell\u2013based immunotherapy: state of the art and beyond. Clin. Cancer Res. 22, 1897\u20131906 (2016).","journal-title":"Clin. Cancer Res."},{"key":"45357_CR21","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","volume":"15","author":"S Anguille","year":"2014","unstructured":"Anguille, S., Smits, E. L., Lion, E., Van Tendeloo, V. F. & Berneman, Z. N. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 15, e257\u2013e267 (2014).","journal-title":"Lancet Oncol."},{"key":"45357_CR22","doi-asserted-by":"publisher","first-page":"e91438","DOI":"10.1172\/jci.insight.91438","volume":"2","author":"S Gross","year":"2017","unstructured":"Gross, S. et al. Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients. JCI Insight 2, e91438 (2017).","journal-title":"JCI Insight"},{"key":"45357_CR23","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00262-010-0942-x","volume":"60","author":"WJ Lesterhuis","year":"2011","unstructured":"Lesterhuis, W. J. et al. Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Cancer Immunol. Immunother. 60, 249\u2013260 (2011).","journal-title":"Cancer Immunol. Immunother."},{"key":"45357_CR24","doi-asserted-by":"publisher","first-page":"5725","DOI":"10.1158\/1078-0432.CCR-11-1261","volume":"17","author":"WJ Lesterhuis","year":"2011","unstructured":"Lesterhuis, W. J. et al. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin. Cancer Res. 17, 5725\u20135735 (2011).","journal-title":"Clin. Cancer Res."},{"key":"45357_CR25","doi-asserted-by":"publisher","first-page":"5779","DOI":"10.1200\/JCO.2005.06.478","volume":"23","author":"IJM de Vries","year":"2005","unstructured":"de Vries, I. J. M. et al. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J. Clin. Oncol. 23, 5779\u20135787 (2005).","journal-title":"J. Clin. Oncol."},{"key":"45357_CR26","doi-asserted-by":"publisher","first-page":"6102","DOI":"10.1158\/0008-5472.CAN-12-2479","volume":"72","author":"EHJG Aarntzen","year":"2012","unstructured":"Aarntzen, E. H. J. G. et al. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell\u2013based vaccination in metastatic melanoma. Cancer Res. 72, 6102\u20136110 (2012).","journal-title":"Cancer Res."},{"key":"45357_CR27","unstructured":"Bol K. F. et al. Adjuvant dendritic cell therapy in stage IIIB\/C melanoma: the MIND-DC randomized phase III trial. Nat. Commun. (2024)."},{"key":"45357_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan, V. et al. Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients. Science 359, 97\u2013103 (2018).","journal-title":"Science"},{"key":"45357_CR29","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson, V. et al. The commensal microbiome is associated with anti\u2013PD-1 efficacy in metastatic melanoma patients. Science 359, 104\u2013108 (2018).","journal-title":"Science"},{"key":"45357_CR30","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","volume":"28","author":"N Chaput","year":"2017","unstructured":"Chaput, N. et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann. Oncol. 28, 1368\u20131379 (2017).","journal-title":"Ann. Oncol."},{"key":"45357_CR31","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41591-022-01695-5","volume":"28","author":"KA Lee","year":"2022","unstructured":"Lee, K. A. et al. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nat. Med. 28, 535\u2013544 (2022).","journal-title":"Nat. Med."},{"key":"45357_CR32","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41591-022-01698-2","volume":"28","author":"JA McCulloch","year":"2022","unstructured":"McCulloch, J. A. et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat. Med. 28, 545\u2013556 (2022).","journal-title":"Nat. Med."},{"key":"45357_CR33","doi-asserted-by":"publisher","unstructured":"Blanco-M\u00edguez, A. et al. Extending and improving metagenomic taxonomic profiling with uncharacterized species using MetaPhlAn 4. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-023-01688-w (2023).","DOI":"10.1038\/s41587-023-01688-w"},{"key":"45357_CR34","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.mib.2013.06.003","volume":"16","author":"S Miquel","year":"2013","unstructured":"Miquel, S. et al. Faecalibacterium prausnitzii and human intestinal health. Curr. Opin. Microbiol. 16, 255\u2013261 (2013).","journal-title":"Curr. Opin. Microbiol."},{"key":"45357_CR35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3389\/fimmu.2019.00143","volume":"10","author":"J Alameddine","year":"2019","unstructured":"Alameddine, J. et al. Faecalibacterium prausnitzii skews human DC to Prime IL10-Producing T cells through TLR2\/6\/JNK Signaling and IL-10, IL-27, CD39, and IDO-1 Induction. Front. Immunol. 10, 143 (2019).","journal-title":"Front. Immunol."},{"key":"45357_CR36","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41571-018-0006-2","volume":"15","author":"B Routy","year":"2018","unstructured":"Routy, B. et al. The gut microbiota influences anticancer immunosurveillance and general health. Nat. Rev. Clin. Oncol. 15, 382\u2013396 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"45357_CR37","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ccell.2019.12.011","volume":"37","author":"S Sivanand","year":"2020","unstructured":"Sivanand, S. & Vander Heiden, M. G. Emerging roles for branched-chain amino acid metabolism in cancer. Cancer Cell 37, 147\u2013156 (2020).","journal-title":"Cancer Cell"},{"key":"45357_CR38","doi-asserted-by":"crossref","unstructured":"Suzek, B. E. et al. Bioinformatics 31, 926\u2013932 (2015).","DOI":"10.1093\/bioinformatics\/btu739"},{"key":"45357_CR39","doi-asserted-by":"publisher","first-page":"D445","DOI":"10.1093\/nar\/gkz862","volume":"48","author":"R Caspi","year":"2020","unstructured":"Caspi, R. et al. The MetaCyc database of metabolic pathways and enzymes - a 2019 update. Nucleic Acids Res. 48, D445\u2013D453 (2020).","journal-title":"Nucleic Acids Res."},{"key":"45357_CR40","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2307\/1942268","volume":"27","author":"JR Bray","year":"1957","unstructured":"Bray, J. R. & Curtis, J. T. An ordination of the upland forest communities of Southern Wisconsin. Ecol. Monogr. 27, 325\u2013349 (1957).","journal-title":"Ecol. Monogr."},{"key":"45357_CR41","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41591-021-01655-5","volume":"28","author":"L Derosa","year":"2022","unstructured":"Derosa, L. et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat. Med. 28, 315\u2013324 (2022).","journal-title":"Nat. Med."},{"key":"45357_CR42","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nmeth.4468","volume":"14","author":"E Pasolli","year":"2017","unstructured":"Pasolli, E. et al. Accessible, curated metagenomic data through ExperimentHub. Nat. Methods 14, 1023\u20131024 (2017).","journal-title":"Nat. Methods"},{"key":"45357_CR43","doi-asserted-by":"publisher","unstructured":"Chen, T. & Guestrin, C. XGBoost: A Scalable Tree Boosting System. in Proc. 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining 785\u2013794 (ACM, 2016). https:\/\/doi.org\/10.1145\/2939672.2939785.","DOI":"10.1145\/2939672.2939785"},{"key":"45357_CR44","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"key":"45357_CR45","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1158\/2159-8290.CD-21-0236","volume":"11","author":"L Derosa","year":"2021","unstructured":"Derosa, L. et al. Microbiota-Centered Interventions: the next breakthrough in immuno-oncology? Cancer Discov. 11, 2396\u20132412 (2021).","journal-title":"Cancer Discov."},{"key":"45357_CR46","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/ibd.20903","volume":"15","author":"H Sokol","year":"2009","unstructured":"Sokol, H. et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm. Bowel Dis. 15, 1183\u20131189 (2009).","journal-title":"Inflamm. Bowel Dis."},{"key":"45357_CR47","doi-asserted-by":"publisher","first-page":"16731","DOI":"10.1073\/pnas.0804812105","volume":"105","author":"H Sokol","year":"2008","unstructured":"Sokol, H. et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. USA 105, 16731\u201316736 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"45357_CR48","doi-asserted-by":"publisher","first-page":"e109146","DOI":"10.1371\/journal.pone.0109146","volume":"9","author":"M Zhang","year":"2014","unstructured":"Zhang, M. et al. Faecalibacterium prausnitzii inhibits interleukin-17 to ameliorate colorectal colitis in rats. PLoS One 9, e109146 (2014).","journal-title":"PLoS One"},{"key":"45357_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7007-11-61","volume":"11","author":"L Wrzosek","year":"2013","unstructured":"Wrzosek, L. et al. Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii influence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent. BMC Biol. 11, 61 (2013).","journal-title":"BMC Biol."},{"key":"45357_CR50","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/01.MIB.0000440815.76627.64","volume":"20","author":"R Mart\u00edn","year":"2014","unstructured":"Mart\u00edn, R. et al. The commensal bacterium Faecalibacterium prausnitzii is protective in DNBS-induced chronic moderate and severe colitis models. Inflamm. Bowel Dis. 20, 417\u2013430 (2014).","journal-title":"Inflamm. Bowel Dis."},{"key":"45357_CR51","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1136\/gutjnl-2014-307649","volume":"65","author":"E Qu\u00e9vrain","year":"2016","unstructured":"Qu\u00e9vrain, E. et al. Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn\u2019s disease. Gut 65, 415\u2013425 (2016).","journal-title":"Gut"},{"key":"45357_CR52","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/intimm\/dxz022","volume":"31","author":"M Zhang","year":"2019","unstructured":"Zhang, M. et al. Faecalibacterium prausnitzii produces butyrate to decrease c-Myc-related metabolism and Th17 differentiation by inhibiting histone deacetylase 3. Int. Immunol. 31, 499\u2013514 (2019).","journal-title":"Int. Immunol."},{"key":"45357_CR53","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.3390\/nu14142945","volume":"14","author":"W Hu","year":"2022","unstructured":"Hu, W. et al. Specific strains of faecalibacterium prausnitzii ameliorate nonalcoholic fatty liver disease in mice in association with gut microbiota regulation. Nutrients 14, 2945 (2022).","journal-title":"Nutrients"},{"key":"45357_CR54","doi-asserted-by":"publisher","first-page":"e00300","DOI":"10.1128\/mBio.00300-15","volume":"6","author":"S Miquel","year":"2015","unstructured":"Miquel, S. et al. Identification of metabolic signatures linked to anti-inflammatory effects of Faecalibacterium prausnitzii. mBio 6, e00300\u2013e00315 (2015).","journal-title":"mBio"},{"key":"45357_CR55","doi-asserted-by":"publisher","first-page":"e154722","DOI":"10.1172\/jci.insight.154722","volume":"7","author":"S Touch","year":"2022","unstructured":"Touch, S. et al. Human CD4+CD8\u03b1+ Tregs induced by Faecalibacterium prausnitzii protect against intestinal inflammation. JCI Insight 7, e154722 (2022).","journal-title":"JCI Insight"},{"key":"45357_CR56","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1158\/2159-8290.CD-21-0999","volume":"12","author":"S Yonekura","year":"2022","unstructured":"Yonekura, S. et al. Cancer induces a stress ileopathy depending on \u03b2-Adrenergic receptors and promoting dysbiosis that contributes to carcinogenesis. Cancer Discov. 12, 1128\u20131151 (2022).","journal-title":"Cancer Discov."},{"key":"45357_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05692-5","volume":"14","author":"N Liu","year":"2023","unstructured":"Liu, N. et al. Supplementation with \u03b1-ketoglutarate improved the efficacy of anti-PD1 melanoma treatment through epigenetic modulation of PD-L1. Cell Death Dis. 14, 170 (2023).","journal-title":"Cell Death Dis."},{"key":"45357_CR58","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12866-020-01739-1","volume":"20","author":"J Ma","year":"2020","unstructured":"Ma, J. et al. Alter between gut bacteria and blood metabolites and the anti-tumor effects of Faecalibacterium prausnitzii in breast cancer. BMC Microbiol. 20, 82 (2020).","journal-title":"BMC Microbiol."},{"key":"45357_CR59","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nri2294","volume":"8","author":"CN Serhan","year":"2008","unstructured":"Serhan, C. N., Chiang, N. & Van Dyke, T. E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8, 349\u2013361 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"45357_CR60","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3389\/fonc.2020.00717","volume":"10","author":"X Liu","year":"2020","unstructured":"Liu, X. et al. LC-MS-based plasma metabolomics and lipidomics analyses for differential diagnosis of bladder cancer and renal cell carcinoma. Front. Oncol. 10, 717 (2020).","journal-title":"Front. Oncol."},{"key":"45357_CR61","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1158\/0008-5472.CAN-14-1703","volume":"75","author":"HI Wettersten","year":"2015","unstructured":"Wettersten, H. I. et al. Grade-dependent metabolic reprogramming in kidney cancer revealed by combined proteomics and metabolomics analysis. Cancer Res. 75, 2541\u20132552 (2015).","journal-title":"Cancer Res."},{"key":"45357_CR62","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/hep.26093","volume":"57","author":"L Zhu","year":"2013","unstructured":"Zhu, L. et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology 57, 601\u2013609 (2013).","journal-title":"Hepatology"},{"key":"45357_CR63","doi-asserted-by":"publisher","first-page":"78","DOI":"10.14218\/JCTH.2014.00037","volume":"3","author":"Q-Q Zhang","year":"2015","unstructured":"Zhang, Q.-Q. & Lu, L.-G. Nonalcoholic fatty liver disease: dyslipidemia, risk for cardiovascular complications, and treatment strategy. J. Clin. Transl. Hepatol. 3, 78\u201384 (2015).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"45357_CR64","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1038\/ismej.2017.24","volume":"11","author":"E Munukka","year":"2017","unstructured":"Munukka, E. et al. Faecalibacterium prausnitzii treatment improves hepatic health and reduces adipose tissue inflammation in high-fat fed mice. ISME J. 11, 1667\u20131679 (2017).","journal-title":"ISME J."},{"key":"45357_CR65","doi-asserted-by":"publisher","first-page":"8882","DOI":"10.1073\/pnas.1307237110","volume":"110","author":"JJ Kamphorst","year":"2013","unstructured":"Kamphorst, J. J. et al. Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc. Natl. Acad. Sci. USA 110, 8882\u20138887 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"45357_CR66","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1158\/0008-5472.CAN-15-2613","volume":"76","author":"OF Kuzu","year":"2016","unstructured":"Kuzu, O. F., Noory, M. A. & Robertson, G. P. The role of cholesterol in cancer. Cancer Res. 76, 2063\u20132070 (2016).","journal-title":"Cancer Res."},{"key":"45357_CR67","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.3390\/cancers12113147","volume":"12","author":"L Pellerin","year":"2020","unstructured":"Pellerin, L. et al. Lipid metabolic reprogramming: role in melanoma progression and therapeutic perspectives. Cancers 12, 3147 (2020).","journal-title":"Cancers"},{"key":"45357_CR68","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3390\/molecules27010152","volume":"27","author":"B Balestrieri","year":"2021","unstructured":"Balestrieri, B., Di Costanzo, D. & Dwyer, D. F. Macrophage-mediated immune responses: from fatty acids to oxylipins. Molecules 27, 152 (2021).","journal-title":"Molecules"},{"key":"45357_CR69","doi-asserted-by":"publisher","first-page":"4640","DOI":"10.4049\/jimmunol.1202312","volume":"190","author":"A Rehman","year":"2013","unstructured":"Rehman, A. et al. Role of fatty-acid synthesis in dendritic cell generation and function. J. Immunol. 190, 4640\u20134649 (2013).","journal-title":"J. Immunol."},{"key":"45357_CR70","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.4049\/jimmunol.174.9.5390","volume":"174","author":"AR Weatherill","year":"2005","unstructured":"Weatherill, A. R. et al. Saturated and polyunsaturated fatty acids reciprocally modulate dendritic cell functions mediated through TLR4. J. Immunol. 174, 5390\u20135397 (2005).","journal-title":"J. Immunol."},{"key":"45357_CR71","doi-asserted-by":"publisher","first-page":"14293","DOI":"10.1074\/jbc.M410000200","volume":"280","author":"M Zeyda","year":"2005","unstructured":"Zeyda, M. et al. Polyunsaturated fatty acids block dendritic cell activation and function independently of NF-\u03baB activation. J. Biol. Chem. 280, 14293\u201314301 (2005).","journal-title":"J. Biol. Chem."},{"key":"45357_CR72","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.jhep.2011.08.025","volume":"56","author":"LP Bechmann","year":"2012","unstructured":"Bechmann, L. P. et al. The interaction of hepatic lipid and glucose metabolism in liver diseases. J. Hepatol. 56, 952\u2013964 (2012).","journal-title":"J. Hepatol."},{"key":"45357_CR73","doi-asserted-by":"publisher","first-page":"eabo2296","DOI":"10.1126\/science.abo2296","volume":"380","author":"M Fidelle","year":"2023","unstructured":"Fidelle, M. et al. A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers. Science 380, eabo2296 (2023).","journal-title":"Science"},{"key":"45357_CR74","doi-asserted-by":"publisher","unstructured":"Beghini, F. et al. Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3. https:\/\/doi.org\/10.1101\/2020.11.19.388223. (2020).","DOI":"10.1101\/2020.11.19.388223"},{"key":"45357_CR75","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/j.1538-7305.1948.tb01338.x","volume":"27","author":"CE Shannon","year":"1948","unstructured":"Shannon, C. E. A Mathematical theory of communication. Bell Syst. Tech. J. 27, 379\u2013423 (1948).","journal-title":"Bell Syst. Tech. J."},{"key":"45357_CR76","unstructured":"Oksanen J, et al. vegan: community ecology package. R package version 2.5-2. (2018)."},{"key":"45357_CR77","doi-asserted-by":"publisher","unstructured":"Rey, D. & Neuh\u00e4user, M. Wilcoxon-Signed-Rank Test. in International Encyclopedia of Statistical Science (ed. Lovric, M.) 1658\u20131659 (Springer Berlin Heidelberg, 2011). https:\/\/doi.org\/10.1007\/978-3-642-04898-2_616.","DOI":"10.1007\/978-3-642-04898-2_616"},{"key":"45357_CR78","doi-asserted-by":"publisher","first-page":"e1009442","DOI":"10.1371\/journal.pcbi.1009442","volume":"17","author":"H Mallick","year":"2021","unstructured":"Mallick, H. et al. Multivariable association discovery in population-scale meta-omics studies. PLoS Comput Biol. 17, e1009442 (2021).","journal-title":"PLoS Comput Biol."},{"key":"45357_CR79","doi-asserted-by":"publisher","first-page":"6375","DOI":"10.18632\/aging.202739","volume":"13","author":"C Grajeda-Iglesias","year":"2021","unstructured":"Grajeda-Iglesias, C. et al. Oral administration of Akkermansia muciniphila elevates systemic antiaging and anticancer metabolites. Aging 13, 6375\u20136405 (2021).","journal-title":"Aging"},{"key":"45357_CR80","doi-asserted-by":"crossref","unstructured":"Durand, S. et al. The intracellular metabolome of starving cells. Methods Cell Biol. 164 137\u2013156 (2021).","DOI":"10.1016\/bs.mcb.2021.04.001"},{"key":"45357_CR81","doi-asserted-by":"publisher","first-page":"eabd7064","DOI":"10.1126\/scitranslmed.abd7064","volume":"13","author":"M Abdellatif","year":"2021","unstructured":"Abdellatif, M. et al. Nicotinamide for the treatment of heart failure with preserved ejection fraction. Sci. Transl. Med. 13, eabd7064 (2021).","journal-title":"Sci. Transl. Med."},{"key":"45357_CR82","doi-asserted-by":"crossref","unstructured":"Kursa, M. B. & Rudnicki, W. R. Feature selection with the boruta package. J. Stat. Soft. 36, 1\u201313 (2010).","DOI":"10.18637\/jss.v036.i11"},{"key":"45357_CR83","doi-asserted-by":"crossref","unstructured":"Buuren, S. V. & Groothuis-Oudshoorn, K. mice: multivariate imputation by chained equations in R. J. Stat. Soft. 45, 1\u201367 (2011).","DOI":"10.18637\/jss.v045.i03"},{"key":"45357_CR84","doi-asserted-by":"publisher","first-page":"e1005752","DOI":"10.1371\/journal.pcbi.1005752","volume":"13","author":"F Rohart","year":"2017","unstructured":"Rohart, F., Gautier, B., Singh, A. & L\u00ea Cao, K.-A. mixOmics: an R package for \u2018omics feature selection and multiple data integration. PLoS Comput Biol. 13, e1005752 (2017).","journal-title":"PLoS Comput Biol."},{"key":"45357_CR85","first-page":"548","volume":"92","author":"B Efron","year":"1997","unstructured":"Efron, B. & Tibshirani, R. Improvements on cross-validation: the .632+ bootstrap method. J. Am. Stat. Assoc. 92, 548 (1997).","journal-title":"J. Am. Stat. Assoc."},{"key":"45357_CR86","doi-asserted-by":"publisher","first-page":"5691","DOI":"10.1002\/sim.9148","volume":"40","author":"H Noma","year":"2021","unstructured":"Noma, H., Shinozaki, T., Iba, K., Teramukai, S. & Furukawa, T. A. Confidence intervals of prediction accuracy measures for multivariable prediction models based on the bootstrap\u2010based optimism correction methods. Stat. Med. 40, 5691\u20135701 (2021).","journal-title":"Stat. Med."},{"key":"45357_CR87","doi-asserted-by":"publisher","unstructured":"Suissa, D. Microbiota-associated metabolic reprograming influenced clinical outcome in the randomized dendritic cell-based clinical trial in stage III melanoma, https:\/\/doi.org\/10.17632\/NZB653783H.1 (2023).","DOI":"10.17632\/NZB653783H.1"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45357-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45357-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45357-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T06:07:31Z","timestamp":1708668451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45357-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["45357"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-45357-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2924093\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"assertion":[{"value":"9 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.Zi. founded EverImmune and is the SAB president of EverImmune. L.ZI. had grant support from Daichi Sankyo, Kaleido, 9 meters and Pileje. A.M.M.E.: consulting fees from Acetra, Agenus, BioInvent, Brenus, CatalYm, Epics, Ellipses, Galecto, GenOway, IO Biotech, IQVIA, ISA Pharmaceuticals, Merck&Co, MSD, Pierre Fabre, Sairopa, Scorpion, Sellas, SkylineDX, TigeTx, Trained Immunity TX. A.M.M.E.: participation on a Data Safety Monitoring Board: Boehringer Ingelheim, BioNTech, and Pfizer. A.M.M.E.: lectures for BMS, MSD. A.M.M.E.: stock or stock options for IO Biotech, SkylineDx and Sairopa. G.K. has been holding research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Tollys, and Vascage. G.K. is on the Board of Directors of the Bristol Myers Squibb Foundation France. G.K. is a scientific co-founder of EverImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio. G.K. is in the scientific advisory boards of Hevolution, Institut Servier and Longevity Vision Funds. G.K. is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis and metabolic disorders. G.K.\u2019s brother, Romano Kroemer, was an employee of Sanofi and now consults for Boehringer-Ingelheim. B.R. is co-founder of Science Curebiota. L.D. is a SAB member of EverImmune. K.F.B.: consulting fees (institutional) from MSD and Pierre Fabre. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1633"}}